REGENERON PHARMACEUTICALS, INC. Deferred Tax Liabilities, Unrealized Gains on Trading Securities
REGENERON PHARMACEUTICALS, INC. (REGN) had Deferred Tax Liabilities, Unrealized Gains on Trading Securities of $1.90 million as of 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities · last filed 2026-02-04
- 2025-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $1.90M.
- 2024-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $93.00M.
- 2023-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $50.40M.
- 2022-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $58.20M.
| Period end | Deferred Tax Liabilities, Unrealized Gains on Trading Securities |
|---|---|
| 2025-12-31 | $1.90M 10-K · filed 2026-02-04 |
| 2024-12-31 | $93.00M 10-K · filed 2026-02-04 |
| 2023-12-31 | $50.40M 10-K · filed 2025-02-05 |
| 2022-12-31 | $58.20M 10-K · filed 2024-02-05 |
| 2021-12-31 | $123.50M 10-K · filed 2023-02-06 |
| 2020-12-31 | $57.70M 10-K · filed 2022-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |